01Identity
Device and system
Console, transducer, focal geometry, cartridge and any integrated imaging determine what the system actually does.
Microfocused Ultrasound / HIFU · Device-Based Treatment · Istanbul
Microfocused Ultrasound / HIFU · Device-Based Treatment · Istanbul
Microfocused Ultrasound / HIFU
Microfocused ultrasound, image-guided systems and devices marketed as HIFU cannot be assumed to share the same transducer, focus, tissue target or authorisation. The name of an energy class does not identify a treatment protocol: the exact device, applicator, tissue path, labelled use and clinical aim must be considered together.
Online information cannot select a device, settings, treatment depth, anatomical path or number of sessions. Final suitability requires an in-person medical examination.
Device Identity
System · energy · preparation · route
A device category is not a complete clinical description.
Four separate identifiers keep unlike systems and unlike tissue effects from being treated as equivalent.
02Mechanism
Energy source
Focused acoustic energy forms discrete thermal or mechanical effects at specified depths; imaging energy and treatment energy have different roles.
03Traceability
Preparation and consumables
Transducer integrity, coupling material, software, maintenance and manufacturer-approved cartridges are verified.
04Tissue path
Invasiveness and route
Energy passes through the surface and converges at a focus; target depth and anatomy cannot be inferred from the term HIFU.
Target and Boundary
Target tissue · clinical aim · realistic limits
The tissue question comes before the machine name.
Skin, connective tissue and subcutaneous structures must be mapped against nerves, vessels, bone and intended labelled tissue.
What a review may establish
- Identify a defined tissue target after examination
- Compare the exact device label with the proposed use
- Set a measurable and limited clinical endpoint
- Keep alternatives and a no-treatment option open
What must not be assumed
- Guarantee regeneration, collagen production, tightening or lifting
- Treat all devices with one marketing name as equivalent
- Predict duration or a fixed session count
- Replace diagnosis, surgery or disease-directed care when these take priority
Microfocused ultrasound, systems with visualisation and broad HIFU marketing terms are not automatically equivalent; labelled uses differ by product and region.
Medical Suitability
Diagnosis and anatomy before device selection
Five checks precede any personal energy plan.
The examination separates the clinical finding, tissue depth, healing risk, device status and proportionate alternatives.
- 01
Confirm the diagnosis
Symptoms, onset, examination and any need for dermoscopic, imaging or specialist assessment come first.
- 02
Map tissue and anatomy
Skin, connective tissue and subcutaneous structures must be mapped against nerves, vessels, bone and intended labelled tissue.
- 03
Review healing and exposure
Neurological history, altered sensation, implants, active disease, prior surgery, low facial fat and inability to map anatomy require careful review.
- 04
Verify the exact system
Microfocused ultrasound, systems with visualisation and broad HIFU marketing terms are not automatically equivalent; labelled uses differ by product and region.
- 05
Define follow-up
A baseline, expected reaction, adverse-effect route and stopping criteria are agreed. Stop for severe or electric pain, weakness, facial asymmetry, sensory loss, burn signs or evolving contour change and arrange medical review.
Device and Treatment Path
Traceability without a public settings recipe
Preparation, delivery and aftercare form one auditable chain.
Transducer integrity, coupling material, software, maintenance and manufacturer-approved cartridges are verified.
01Before
Verify device and patient
Identity, manufacturer instructions, labelled use, maintenance, consumables and patient-specific exclusions are checked.
- Record the exact system
- Confirm consumable integrity
- Complete safety checks
02During
Control the tissue path
Energy passes through the surface and converges at a focus; target depth and anatomy cannot be inferred from the term HIFU.
- Protect vulnerable structures
- Monitor tissue response
- Stop if safety limits are crossed
03After
Connect observation to follow-up
Stop for severe or electric pain, weakness, facial asymmetry, sensory loss, burn signs or evolving contour change and arrange medical review.
- Document the treated region
- Explain expected reactions
- Provide an escalation route
Public information does not provide wavelength, depth, fluence, power, pulse, pass, cartridge, transducer or anatomical treatment settings.
Evidence and Limits
Device-, indication- and endpoint-specific
Evidence for one system cannot be generalised to an entire marketing class.
Evidence is device- and indication-specific and does not establish equivalence to surgical lifting or a guaranteed duration.
Keep the device exact
Applicator design, energy delivery, feedback and tissue control may differ between systems.
Keep the indication exact
Evidence in one diagnosis, body area or skin type does not establish another use.
Read endpoints carefully
Short-term appearance scores, photographs, symptoms and histology are not interchangeable outcomes.
Retain uncertainty
Comparative effectiveness, durability and uncommon harms may remain uncertain.
Manufacturer information may identify a product and its instructions, but it is not treated as independent evidence of a general class effect.
Individual Plan
One device · one target · one review point
A proportionate plan includes a reason not to proceed.
Selection follows diagnosis, device identity, labelled context, tissue target, risk and realistic alternatives.
Name the target
Skin, connective tissue and subcutaneous structures must be mapped against nerves, vessels, bone and intended labelled tissue.
Name the system
Console, transducer, focal geometry, cartridge and any integrated imaging determine what the system actually does.
Name the endpoint
Record what change would be clinically meaningful and when it can reasonably be reviewed.
Name the exit
Stop for severe or electric pain, weakness, facial asymmetry, sensory loss, burn signs or evolving contour change and arrange medical review.
Course and Follow-Up
Expected reaction · adverse effect · stopping
Reassessment is part of the treatment, not an afterthought.
The follow-up pathway distinguishes an expected short response from a complication or an absent clinical reason to repeat.
- 01Same day
Immediate review
Comfort, skin response and any unexpected neurological, vascular or thermal sign are checked.
- 02Early
Early healing
Pain, swelling, blistering, crusting, discharge, colour change or asymmetry are reviewed as relevant.
- 03Later
Clinical endpoint
Comparable records assess the agreed target without attributing every change to the device.
- 04Decision
Continue, change or stop
Stop for severe or electric pain, weakness, facial asymmetry, sensory loss, burn signs or evolving contour change and arrange medical review.
Risks and Alternatives
Energy, tissue path and anatomy shape harm
Serious and delayed adverse effects remain visible.
Pain, burns, numbness, nerve injury, motor weakness, fat loss, contour change and unintended tissue damage may occur.
01
Expected reactions
Temporary pain, redness, swelling, tenderness or surface change may occur depending on the system and route.
02Safety
Complications
Pain, burns, numbness, nerve injury, motor weakness, fat loss, contour change and unintended tissue damage may occur.
03Options
Alternatives
Observation, skin care, other energy devices, injectable or surgical assessment, or no treatment
04Decision
Withhold or stop
Treatment is withheld or stopped when the indication, consent, safety controls or follow-up cannot support a proportionate plan.
Treatment is withheld when diagnosis, device status, anatomy, consent or follow-up is inadequate. Stop for severe or electric pain, weakness, facial asymmetry, sensory loss, burn signs or evolving contour change and arrange medical review.
Istanbul and Follow-Up
Assessment and safety must travel together
International care requires a workable review route.
Travel planning does not shorten observation or remove the need for local medical access.
01Before travel
Organise the question
History and comparable photographs prepare discussion without confirming a device.
02In Istanbul
Examine in person
Diagnosis, anatomy, device, label, risks and alternatives are reviewed together.
03Treatment day
Keep exact records
System, consumable, treated region and observations remain traceable.
04After return
Plan escalation
Stop for severe or electric pain, weakness, facial asymmetry, sensory loss, burn signs or evolving contour change and arrange medical review.
The Doctor Aslan Approach
Device-specific, anatomy-led and evidence-bounded
The machine follows the medical decision.
Doctor Aslan separates device identity, energy path, tissue target, authorisation and evidence before discussing a personal plan.
Diagnose first
Do not use an energy label as a substitute for a clinical diagnosis.
Audit the system
Verify manufacturer, model, applicator, consumable, maintenance and labelled use.
Protect anatomy
Match invasiveness and energy path to vulnerable structures and healing risk.
Accept no treatment
Withholding treatment remains appropriate when expected benefit or safety is insufficient.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about Microfocused Ultrasound / HIFU; no personal settings or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is Microfocused Ultrasound / HIFU?+
Microfocused Ultrasound / HIFU is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for Microfocused Ultrasound / HIFU?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Define the finding · identify the system · compare alternatives